Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;35(12):3589-3593.
doi: 10.1038/s41375-021-01314-1. Epub 2021 Jun 10.

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Ron D Jachimowicz #  1   2   3   4 , Wolfram Klapper #  5 , Gunther Glehr  6 , Horst Müller  7 , Heinz Haverkamp  7 , Christoph Thorns  8 , Martin Leo Hansmann  9 , Peter Möller  10 , Harald Stein  11 , Thorsten Rehberg  6 , Bastian von Tresckow  7   12 , H C Reinhardt  12 , Peter Borchmann  7 , Fong Chun Chan  13 , Rainer Spang  6 , David W Scott  13 , Andreas Engert  7 , Christian Steidl  13 , Michael Altenbuchinger  6   14 , Andreas Rosenwald  15
Affiliations

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Ron D Jachimowicz et al. Leukemia. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Employment or Leadership Position: None; Consultant or Advisory Role: AE, Takeda, BMS; HCR, Abbvie, AstraZeneca; BvT, Amgen, Pfizer, Takeda, MSD; WK, Takeda; CS Seattle Genetics, Curis Inc., Roche, AbbVie, AstraZeneca, Juno Therapeutics, Bayer; Stock Ownership: None; Honoraria: AE, Takeda, BMS, WK, Takeda; BvT, Roche, Takeda, MSD; Research Funding: AE, Takeda, BMS, Affimed; HCR, Gilead Sciences; BvT, Novartis, MSD, Takeda; WK, Takeda, Amgen, Regeneron, Roche; CS. Bristol-Myers Squibb, Epizyme and Trillium Therapeutics Inc.; Expert Testimony: None; Other Remuneration: None

Figures

Fig. 1
Fig. 1. Kaplan–Meier survival curves for the 23-gene adjusted prognostic gene predictor in 401 patients with advanced stage cHL treated within clinical trials HD12 and HD15.
A PFS comparing 23-gene adjusted prognostic gene predictor positive (red) and negative (blue) cohorts. B OS comparing 23-gene adjusted prognostic gene predictor positive (red) and negative (blue) cohorts. C OS comparing 23-gene adjusted prognostic gene predictor high-risk (red: age < 45; green: age ≥ 45) and low-risk (blue: age < 45; purple: age ≥ 45) cohorts. D OS comparing 23-gene adjusted prognostic gene predictor high-risk (red: female sex; green: male sex) and negative (blue: female sex; purple: male sex) cohorts.
See this image and copyright information in PMC

References

    1. Eichenauer DA, Engert A, Andre M, Federico M, Illidge T, Hutchings M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii70–5. doi: 10.1093/annonc/mdu181. - DOI - PubMed
    1. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013;31:692–700. doi: 10.1200/JCO.2012.43.4589. - DOI - PMC - PubMed
    1. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29:4234–42. doi: 10.1200/JCO.2010.33.9549. - DOI - PubMed
    1. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9. doi: 10.1016/S0140-6736(11)61940-5. - DOI - PubMed
    1. Jachimowicz RD, Pieper L, Reinke S, Gontarewicz A, Plutschow A, Haverkamp H, et al. Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica. 2020;106:1684–92. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts